Cigall Kadoch

Cigall Kadoch is an American biochemist and cancer biologist who is a Professor and Meredith Beaton Starr and Billy Starr Investigator in the Department of Pediatric Oncology at the Dana–Farber Cancer Institute and Harvard Medical School and an Investigator at the Howard Hughes Medical Institute. Her research is focused in chromatin regulation and how changes in cellular structure can lead to human diseases, such as Cancer, Neurodevelopmental disorders, and others. She is internationally recognized for her work on the mammalian SWI/SNF complex, a large molecular machine known as a Chromatin remodeling complex. She was named as one of the world's leading scientists by MIT Technology Review, 35 Under 35 and Forbes 30 Under 30, and was named the Laureate in the Life Sciences for the Blavatnik National Awards for Young Scientists. In 2019, she received the Martin and Rose Wachtel Cancer Research Prize from the American Association for the Advancement of Science and in 2020, the American Association for Cancer Research Outstanding Achievement in Basic Cancer Research Award. Kadoch was also recognized as one of the 100 Most Influential Women in Oncology by OncoDaily.

Early life and education Kadoch was born and raised in Marin County, California, just north of San Francisco. As a teenager, she lost a close family friend to late-stage breast cancer, which inspired her to learn more about the disease. Whilst completing her doctorate, she identified a relationship between the SWI/SNF (BAF) chromatin remodeling protein complex and synovial sarcoma. After completing her doctorate at Stanford University she transitioned directly to faculty at Dana–Farber Cancer Institute and Harvard Medical School. She has since studied mammalian SWI/SNF complexes in an effort to develop new therapeutic strategies.

The SWI/SNF complexes serve to open and close DNA, altering which genes are expressed at particular times. Kadoch's work showed that mutations in the SWI/SNF (BAF) protein complex are involved in over 20% of human cancers. Further, Kadoch identified that 100% of synovial sarcoma tumors have defects in one particular subunit of SWI/SNF complex, which drives disease pathogenesis. The fusion oncoprotein subunit, SS18-SSX, appears to break the guidance system of SWI/SNF (BAF), targeting it aberrantly on chromatin and activating genes that support cancer development. In lab-based experiments, Kadoch showed that it was possible to use healthy subunits to repair the complex and kill the cancerous cells. The spin-out company launched on the Nasdaq in 2020, with a $120 million initial public offering.

Awards and honors NIH Director's New Innovator Award Pew Scholar Award American Association for the Advancement of Sciences Marin and Rose Wachtel Cancer Research Prize American Association for Cancer Research Outstanding Achievement Award Forbes 30 under 30 List MIT Technology Review 35 Innovators Under 35 Popular Science Brilliant 10 Business Insider Top 30 Young leaders in Biopharma Blavatnik National Awards Finalist

Selected publications